Provided by Tiger Trade Technology Pte. Ltd.

IN8bio, Inc.

1.78
-0.0700-3.78%
Post-market: 1.780.00000.00%18:36 EST
Volume:29.57K
Turnover:54.42K
Market Cap:17.38M
PE:-0.28
High:1.90
Open:1.81
Low:1.78
Close:1.85
52wk High:9.86
52wk Low:1.17
Shares:9.76M
Float Shares:9.15M
Volume Ratio:0.70
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3610
EPS(LYR):-17.0525
ROE:-189.72%
ROA:-80.39%
PB:1.32
PE(LYR):-0.10

Loading ...

Company Profile

Company Name:
IN8bio, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
17
Office Location:
350 5th Avenue,Suite 5330,New York,New York,United States
Zip Code:
10118
Fax:
- -
Introduction:
IN8bio, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. It is conducting two investigator-initiated Phase 1 clinical product candidates comprising INB-200, a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors; and INB-100, an allogeneic product candidate for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was founded in 2016 and is based in New York, New York.

Directors

Name
Position
Alan S. Roemer
Chairman of the Board
William Ho
President,Chief Executive Officer and Director
Corinne Epperly
Independent Director
Emily T. Fairbairn
Independent Director
Jeremy Graff
Independent Director
Luba Greenwood
Independent Director
Peter Brandt
Independent Director

Shareholders

Name
Position
William Ho
President,Chief Executive Officer and Director
Kate Rochlin
Chief Operating Officer and President
Patrick McCall
Chief Financial Officer
Lawrence Lamb
Executive Vice President, Chief Scientific Officer and Co-Founder